Lord, Abbett & Co
ACHN

Lord, Abbett & Co’s Achillion Pharmaceuticals ACHN Stock Holding History

Lord, Abbett & Co’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-195,000
Closed -$1.92M – 1012
2015
Q1 		$1.92M Buy
195,000
+35,000
+22% +$437K ﹤0.01% 857
2014
Q4 		$1.96M Sell
160,000
-179,920
-53% -$2.2M 0.01% 864
2014
Q3 		$3.39M Buy
339,920
+5,590
+2% +$51.9K 0.01% 808
2014
Q2 		$2.53M Buy
+334,330
New +$1.33M 0.01% 917
2013
Q3 		– Sell
-317,585
Closed -$2.6M – 1120
2013
Q2 		$2.6M Buy
+317,585
New +$2.42M 0.01% 914

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Lord, Abbett & Co's ACHN Position: Q2 2015 in Review

Lord, Abbett & Co sold out of Achillion Pharmaceuticals (ACHN) in Q2 2015, closing a stake of 195,000 shares — an estimated $1.92M sold.

Lord, Abbett & Co first reported a position in ACHN in Q2 2013 and held it in 5 quarters. The position peaked at $3.39M in Q3 2014. 158 funds tracked by Wall St. Rank hold ACHN as of Q2 2015.

  • Lord, Abbett & Co reported no remaining Achillion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Lord, Abbett & Co sold 195,000 Achillion Pharmaceuticals shares in Q2 2015, an estimated $1.92M.
  • Lord, Abbett & Co first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Lord, Abbett & Co's Achillion Pharmaceuticals position peaked at $3.39M in Q3 2014.
  • 158 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2015.

Based on Lord, Abbett & Co's 13F filing for Q2 2015, filed 14 Aug 2015.